Company intelligence / Profile preview
TRIM-edicine
Columbus, Ohio, USAtrim-edicine.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
ATAP-M8 has completed preclinical studies and received approval to start Phase I clinical trial with late-stage cancer patients for various cancers on March 1, 2022[2]. The company was preparing IND filing materials with US FDA targeting to be ready for US IND filing before the end of 2023[2].
- Therapeutic areas
- OtherOncologyRare DiseasesNeurology
- Modalities
- Recombinant proteinsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on TRIM-edicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIM-edicine.